Project Grant HT94252510252
Award Date
7/1/25
Completion Date
6/30/29
Dollars Obligated
$2.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Denver, CO 80207, USA
Similar Awards
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), awarded a $628,292 project grant to the Boston VA Research Institute, Inc. The funding supports advanced biomedical research focused on investigating military-related toxic exposures as a risk factor for amyotrophic lateral sclerosis (ALS). The 3-year project grant, active from July 1, 2024 to June 30, 2027, will be conducted by the non-profit Boston VA...
The U.S. Department of Defense's Defense Health Agency has awarded a $931,500 Project Grant to The Johns Hopkins University to develop a RIPK2 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). This grant is funded through the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the general public. The research project, which has a performance...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
The U.S. Department of the Army Medical Command has awarded a $1,210,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Mayo Clinic in Rochester, Minnesota. The grant will fund a 3-year research project titled "Exploring Novel ALS Biomarkers: Multiomics Approach Utilizing Immunoprofiling, Extracellular Vesicle Analysis, and TDP-43 Aggregation Assays." The research aims to identify new biomarkers for amyotrophic lateral sclerosis (ALS)...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Department of the Army Medical Command awarded Dartmouth College a $962,758 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop TDP43-specific human CAR T-cells as a therapy for amyotrophic lateral sclerosis (ALS). The grant, with a performance period from July 1, 2024 to June 30, 2026, will support Dartmouth's research into manufacturing and evaluating this novel CAR T-cell immunotherapy for treating ALS, a devastating neurodegenerative disease...
Emory University was awarded a $468,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2021 through August 31, 2023. The grant funds the development of RASCH-built outcome measures to improve clinical trials for amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports biomedical research to transform military and public health care,...
This $1,181,251 Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) program supports research at the University of California, Los Angeles (UCLA) to develop neuronal exosome-based biomarkers for the diagnosis and monitoring of amyotrophic lateral sclerosis (ALS) disease progression. The 3-year award, commencing on April 15, 2025, will enable UCLA's research team to investigate innovative approaches to leveraging neuronal...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...